E2F7 & E2F8 in the control of transcription and cellular proliferation
E2F7
基本信息
- 批准号:8204520
- 负责人:
- 金额:$ 30.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-12-10 至 2012-11-30
- 项目状态:已结题
- 来源:
- 关键词:Admission activityAffinity ChromatographyAnimalsApoptosisApplications GrantsBindingBiochemicalBiologicalCell CycleCell Cycle RegulationCell ProliferationChIP-on-chipCommitComplexCritiquesDataData CollectionDevelopmentEventFamilyFamily memberFutureGene ExpressionGene TargetingGenesGeneticGenetic TranscriptionGoalsHomoIndividualKnock-outLaboratoriesLightMeasuresMediatingMindMolecularMultiprotein ComplexesMusOncogenicPatternPhosphotransferasesPlayPositioning AttributePrincipal InvestigatorProteinsPublished CommentReagentRecruitment ActivityResearchRoleSignal PathwaySorting - Cell MovementStructureSystemTechnologyTestingTissuesTranscription Repressor/CorepressorTumor Suppressor ProteinsWheatWorkarmcombinatorialfallsinterestknowledge basememberoverexpressionprogramspromotertooltranscription factor
项目摘要
The E2F family of transcription factors is believed to play a critical role in the control of cellular
proliferation. These factors are encoded by distinct genes and have both tumor suppressor and oncogenic
functions (1-2). Our laboratory identified E2F7 and E2F8 as the final two members of this transcription factor
family (5, 6). The preliminary data presented in this proposal highlight several unique features of these two
E2Fs that place them in a subclass of their own. These salient features include their ability to form
homodimers and heterodimers, to associate with a large cadre of transcriptional co-repressors, to silence
gene expression, and to block cellular proliferation. While they lack a typical Rb-binding domain, E2F7 can
specifically interact with Rb related proteins and can thus recruit E2F8 to Rb-containing complexes. As a
result, the E2F7/8 arm of the E2F network remains under the control of the cycling dependent kinase (CDK)
signaling pathway. The fact that E2F7 and E2F8 have an identical pattern of cell cycle dependent and tissue-
specific expression, together with their ability to homo- and hetero-dimerize, raises the possibility that they
may have both unique and shared functions in the animal. A multi-faceted effort in the laboratory has yielded
key technical developments, including an affinity purification strategy to purify E2F7/8-associated proteins,
promoter-array technologies to identify target genes, and gene targeting approaches to disrupt E2F7 and
E2F8 in mice. These advances place our research group in a strong position to make significant advances
towards a mechanistic understanding of how this important arm of the E2F family of factors controls the cell
cycle and cell proliferation. The overarching hypothesis of this proposal is that E2F7 and E2F8 function as
transcriptional repressors to negatively control cellular proliferation. Three specific aims utilizing biochemical,
biophysical, global gene array, and genetic approaches will directly test this hypothesis: Specific Aim 1. To
identify and characterize E2F7- and E2F8-associated macromolecular protein complexes. Specific Aim 2.
To identify E2F7 and E2F8 transcriptional targets. Specific Aim 3. To determine the mechanism of E2F7 and
E2F8 action in the control of transcription. This work will elucida the individual and combinatorial
contributions made by these two highly related family members towards the overall understanding of E2F
transcriptional activity.
Project Description Page 6
转录因子的E2 F家族被认为在细胞凋亡的控制中起关键作用。
增殖这些因子由不同的基因编码,具有肿瘤抑制和致癌作用。
函数(1-2)。我们的实验室确定E2 F7和E2 F8是该转录因子的最后两个成员
家庭(5,6)。本提案中提出的初步数据突出了这两个国家的几个独特特征。
E2 F将它们放在自己的子类中。这些显著的特征包括它们能够形成
同源二聚体和异源二聚体,与大量转录辅阻遏物结合,沉默
基因表达,并阻断细胞增殖。虽然它们缺乏典型的Rb结合结构域,但E2 F7可以
E2 F8与Rb相关蛋白特异性相互作用,因此可以将E2 F8募集到含Rb的复合物中。作为
结果,E2 F网络的E2 F7/8臂仍然处于循环依赖性激酶(CDK)的控制下。
信号通路事实上,E2 F7和E2 F8具有相同的细胞周期依赖性和组织-
特异性表达,以及它们同源和异源二聚化的能力,提高了它们
可能在动物身上既有独特的功能又有共同的功能。在实验室的多方面努力已经产生了
关键的技术发展,包括纯化E2 F7/8相关蛋白的亲和纯化策略,
启动子阵列技术来鉴定靶基因,以及基因靶向方法来破坏E2 F7和
小鼠中的E2 F8。这些进步使我们的研究小组处于有利地位,可以取得重大进展
对E2 F家族的这一重要因子如何控制细胞的机制的理解
周期和细胞增殖。该提议的首要假设是E2 F7和E2 F8的功能是
转录抑制因子负控制细胞增殖。三个具体目标利用生化,
生物物理学、全球基因阵列和遗传学方法将直接检验这一假设:具体目标1。到
鉴定和表征E2 F7-和E2 F8-相关大分子蛋白质复合物。具体目标2。
鉴定E2 F7和E2 F8转录靶点。具体目标3。为了确定E2 F7的作用机制,
E2 F8在转录控制中的作用。这项工作将阐明个人和组合
这两个高度相关的家庭成员对E2 F的整体理解所做的贡献
转录活性
项目描述第6页
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GUSTAVO Walter LEONE其他文献
GUSTAVO Walter LEONE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GUSTAVO Walter LEONE', 18)}}的其他基金
Tumor suppressor roles of E2F7 & E2F8 in hepatocellular carcinoma
E2F7 的肿瘤抑制作用
- 批准号:
9457804 - 财政年份:2017
- 资助金额:
$ 30.19万 - 项目类别:
Medical University of South Carolina - Cancer Center Support Grant
南卡罗来纳医科大学 - 癌症中心支持补助金
- 批准号:
9248275 - 财政年份:2009
- 资助金额:
$ 30.19万 - 项目类别:
E2F7 & E2F8 in the control of transcription and cellular proliferation
E2F7
- 批准号:
7389747 - 财政年份:2007
- 资助金额:
$ 30.19万 - 项目类别:
Tumor Suppressor Roles of E2F7 & E2F8 in Hepatocellular Carcinoma (HCC)
E2F7 的肿瘤抑制作用
- 批准号:
8698044 - 财政年份:2007
- 资助金额:
$ 30.19万 - 项目类别:
E2F7 & E2F8 in the control of transcription and cellular proliferation
E2F7
- 批准号:
7539216 - 财政年份:2007
- 资助金额:
$ 30.19万 - 项目类别:
E2F7 & E2F8 in the control of transcription and cellular proliferation
E2F7
- 批准号:
7749926 - 财政年份:2007
- 资助金额:
$ 30.19万 - 项目类别:
相似海外基金
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10506915 - 财政年份:2021
- 资助金额:
$ 30.19万 - 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10325006 - 财政年份:2021
- 资助金额:
$ 30.19万 - 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
- 批准号:
1746198 - 财政年份:2018
- 资助金额:
$ 30.19万 - 项目类别:
Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
- 批准号:
512537-2017 - 财政年份:2017
- 资助金额:
$ 30.19万 - 项目类别:
University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
- 批准号:
1404605 - 财政年份:2014
- 资助金额:
$ 30.19万 - 项目类别:
Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
- 批准号:
1263713 - 财政年份:2013
- 资助金额:
$ 30.19万 - 项目类别:
Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
- 批准号:
425749-2012 - 财政年份:2012
- 资助金额:
$ 30.19万 - 项目类别:
Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
- 批准号:
1159886 - 财政年份:2012
- 资助金额:
$ 30.19万 - 项目类别:
Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
- 批准号:
19560760 - 财政年份:2007
- 资助金额:
$ 30.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
- 批准号:
234753-2000 - 财政年份:2003
- 资助金额:
$ 30.19万 - 项目类别:
Collaborative Research and Development Grants














{{item.name}}会员




